Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

In the Media

  • June 29, 2022

The Intersection Between Medical and Health & Wellness: Force For Knowledge Cannabis Symposium Panel Discussion

InMed Pharmaceuticals’ Dr. Shane Johnson and Radicle Science’s Dr. Jeff Chen join the Force Family Office’s Force For Knowledge Cannabis Symposium: The Intersection Between Medical and Health & Wellness to talk about the importance of evidence-based research of cannabinoids. They discuss the need to provide medical professionals and consumers data and research-supported information to enable informed decision making.

They discuss the increasing interest in the physiological effects of rare cannabinoids and how recent research is unveiling the potential benefits. Radicle Science is conducting a large scale study, “Radicle Energy rare cannabinoid study”, on the effects of THCV on energy, focus/attention, appetite and weight/BMI.

Panel 3: The Intersection Between Medical and Health & Wellness
A discussion of the opportunities in pharmaceutical industry in addition to current health & wellness uses.

  • Shane Johnson, SVP, BayMedica a Division of InMed Pharmaceuticals
  • Jeff Chen, MD & MBA, CEO & Co-founder, Radicle Science
  • Mitch Baruchowitz, Founder & Managing Partner, Merida Capital Holdings

Event website: https://forcefamilyoffice.com/events/technology/force-for-knowledge-cannabis-symposium-panel-3-view-on-demand/

Panel discussion here: https://vimeo.com/725509153

 

Full Article
Source: Force Family Office

Share this post

Latest Articles

Conference Presentation – InMed Presents at Life Sciences Forum December 11, 2025

In this update on InMed Pharmaceuticals, CEO Eric A. Adams talks about the company’s Alzheimer’s disease program. Mr. Adams talks about the role of inflammation

Read More
January 12, 2026

Fierce Biotech Article: Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Risk

Article featured in Fierce Biotech October 16, 2025 Excerpt:  New findings discussed at the latest Alzheimer’s Association International Conference (AAIC) highlight the risk factors associated

Read More
October 27, 2025

InMed Presents at the 2025 Life Sciences Investor Forum

Video Replay Now Available: InMed’s CEO, Eric A. Adams, presents at the 2025 Life Sciences Investor Forum. In the presentation, which was originally published on

Read More
October 14, 2025
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2026 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*